Novo Nordisk has announced compelling results from its phase 3b STEP UP clinical trial, demonstrating that a higher 7.2 mg dose of its weight-loss medication, Wegovy® (semaglutide), led to a significant average weight loss of 21% in adults with obesity.
Novo Nordisk
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
